Stereotactic Radiotherapy for Non-small Cell Lung Cancer with Small Lesions Applying A Flattening Filter Free Clinac
10.3779/j.issn.1009-3419.2015.05.08
- VernacularTitle:NSCLC肺部小病灶非均整模式立体定向放疗的应用
- Author:
GENG JIANHAO
1
;
SHI ANHUI
;
YU RONG
;
WU HAO
;
ZHU GUANGYING
Author Information
1. 100142北京，北京大学临床肿瘤学院，北京大学肿瘤医院暨北京市肿瘤防治研究所放射治疗科，恶性肿瘤发病机制及转化研究教育部重点实验室
- Keywords:
Lung neoplasms;
Stereotactic body radiation therapy;
Flattening iflter free
- From:
Chinese Journal of Lung Cancer
2015;(5):301-307
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective With the rapid development of technology, stereotactic radiotherapy has been widely used. In a cohort of medically operable non-small cell lung cancer patients receiving stereotactic body radiation therapy (SBRT) survival rates“potentially equivalent to those of surgery”have been reported. Removing the ifeld lfattening iflter, Clinac is capable of delivering dose rates much higher than conventional linac as well as reducing the treatment time. hTe goals of this work were to report safety and effcacy of SBRT treatment using a lfattening iflter-free model for non-small cell lung cancer (NSCLC) with small lesions. Methods From December 2011 to December 2013, 31 NSCLC patients who were T1-2N0M0, solitary pulmonary recurrence atfer surgery, and stage IV with oligo metastasis were enrolled, receiving SBRT treatment (60 Gy/8 f or 48 Gy/4 f ) applying a lfattening iflter-free model. Results Compared with conventional technique, lfat-tening iflter-free model shortened the treating time with equivalent target dose and normal tissue dose. hTe median follow-up time is 19.4 mo. hTe 1-yr local control, regional control, distant control, progression free survival and overall survival rates were 96.8%, 96.8%, 83.9%, 77.4%and 96.8%. hTe most common side effects were radiation pneumonitis (29%grade 1, 3.2%grade 2) and chest pain (12.9%grade 1, 6.5%grade 2). Conclusion hTe use of lfattening iflter-free model in SBRT for small lesions of NSCLC patients is safe and effective. Long time follow-up and additional studies are still needed to validate our conclusions.
